Key Takeaways
- Novo Nordisk's weight-loss dominance falters due to rising competition and generic alternatives.
- Big Tech giants Meta and Microsoft posted strong earnings, driven by advertising and AI growth.
- Tariff threats prompted a surge in iPhone sales but also sparked broader market declines.
Deep Dives
Ozempic Rivalry
- Novo Nordisk cut guidance and appointed a new CEO as Eli Lilly and compounding pharmacies erode its weight-loss drug market share.
- The pharmaceutical giant's stock plummeted 33% amid heightened competition for its popular Ozempic and Wegovy drugs.
Tech Resilience
- Meta Platforms exceeded sales and net income expectations, with 22% revenue growth driven by its robust ad business and AI advancements.
- Microsoft's cloud computing and AI demand boosted earnings, propelling its market capitalization above $4 trillion.
Tariff Turmoil
- Anticipation of new tariffs spurred a 13% rise in iPhone sales last quarter, but Apple projects a $1.1 billion tariff cost increase.
- Broader market indices, including the Dow, S&P 500, and NASDAQ, experienced weekly declines as new tariffs spurred investor unease.